Metagenomi (NASDAQ:MGX) Issues Quarterly Earnings Results, Misses Expectations By $0.01 EPS

Metagenomi (NASDAQ:MGX) released its earnings results on Monday. The company reported ($0.61) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.01), FiscalAI reports. The firm had revenue of $1.25 million during the quarter, compared to analysts’ expectations of $5.90 million. Metagenomi had a negative return on equity of 47.14% and a negative net margin of 348.54%.

Metagenomi Stock Performance

MGX traded down $0.06 during trading on Monday, reaching $1.36. 181,161 shares of the company traded hands, compared to its average volume of 230,506. Metagenomi has a 12-month low of $1.25 and a 12-month high of $3.95. The firm has a fifty day simple moving average of $1.45 and a 200 day simple moving average of $1.69. The company has a market cap of $51.02 million, a P/E ratio of -0.57 and a beta of 0.63.

Institutional Investors Weigh In On Metagenomi

A number of institutional investors have recently added to or reduced their stakes in MGX. BNP Paribas Financial Markets grew its holdings in Metagenomi by 1,840.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 15,171 shares of the company’s stock valued at $36,000 after buying an additional 14,389 shares in the last quarter. Bank of America Corp DE grew its holdings in Metagenomi by 508.5% during the 3rd quarter. Bank of America Corp DE now owns 18,766 shares of the company’s stock valued at $44,000 after buying an additional 15,682 shares in the last quarter. Panagora Asset Management Inc. purchased a new stake in Metagenomi during the 4th quarter valued at approximately $53,000. Quadrature Capital Ltd purchased a new stake in Metagenomi during the 4th quarter valued at approximately $55,000. Finally, Dynamic Technology Lab Private Ltd purchased a new stake in Metagenomi during the 3rd quarter valued at approximately $64,000.

Analyst Ratings Changes

MGX has been the subject of several analyst reports. Wall Street Zen lowered shares of Metagenomi from a “hold” rating to a “sell” rating in a report on Saturday, March 21st. Weiss Ratings raised shares of Metagenomi from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, May 1st. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Metagenomi has a consensus rating of “Moderate Buy” and an average target price of $10.00.

Metagenomi Company Profile

Metagenomi, Inc (NASDAQ: MGX) is a biotechnology company that specializes in the discovery and engineering of novel proteins and enzymes using metagenomics and CRISPR-based genome editing. The company’s proprietary platform integrates vast environmental DNA libraries with advanced machine learning and high-throughput screening to identify, optimize and commercialize enzymes for industrial, agricultural and pharmaceutical applications. By tapping into genetic diversity found in nature, Metagenomi aims to accelerate the development of tailored biocatalysts that improve process efficiency, reduce costs and support sustainability initiatives.

Metagenomi’s technology offerings include custom enzyme discovery services, protein engineering tools and licensing of optimized biocatalysts to partners across multiple sectors.